← ANALYST RATINGS · TIPRANKS

Schrodinger (SDGR): analyst forecast and price target

$22.60 −11.30% close 16.10.26 · market cap $1.9B · Healthcare · Software - Application IWM 0.05%
Price targets and ratings of

Analyst consensus

Moderate Buy

4 Buy2 Hold0 Sell

Ratings of 6 analysts in the last 3 months

12-month forecast

$25.80+14.2% upside

Based on 6 price targets given in the last 3 months, the average target is $25.80, the highest $32.00, the lowest $17.00. The average is +14.2% from the last price of $22.60.

$10.00$20.00$30.00Jan 26AprJulOctJan 27AprJulOctHigh$32.00Average$25.80Low$17.00
Highest target $32.00 Average target $25.80 Lowest target $17.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Scott Schoenhaus★★★★★★★★★★#12104 · hits 35% · avg −9.7% KeyBanc $20.00 → $32.00+60.0% Buy +41.6% Reiterated 16.10.26on TipRanks 05:12 −10.2%
Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% TD Cowen $20.00 → $31.00+55.0% Buy +37.2% Assigned 13.10.26on TipRanks 09:00 −0.1%next day −2.2%
Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% BMO Capital $24.00 → $30.00+25.0% Buy +32.7% Reiterated 12.10.26on TipRanks 08:55 −5.0%next day −0.1%
Craig Hettenbach★★★★★★★★★★#1537 · hits 59% · avg +7.6% Morgan Stanley $17.00 Hold −24.8% Reiterated 15.09.26on TipRanks 07:25 +12.5%next day +3.4% · 5 days +29.7%
Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% BMO Capital $24.00 Buy +6.2% Reiterated 17.08.26on TipRanks Aug 18 07:35 −0.6%next day +2.2% · 5 days +9.1%
Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% UBS $13.00 → $19.00+46.2% Hold −15.9% Initiated 14.08.26on TipRanks 05:35 −4.5%next day −0.6% · 5 days +13.4%
Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% Bank of America Securities — Buy — Reiterated 06.08.26on TipRanks 15:05 +8.8%next day +1.4% · 5 days +2.4%
Scott Schoenhaus★★★★★★★★★★#12104 · hits 35% · avg −9.7% KeyBanc $20.00 Buy −11.5% Reiterated 06.08.26on TipRanks 04:16 +8.8%next day +1.4% · 5 days +2.4%
Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% TD Cowen $20.00 Buy −11.5% Reiterated 05.08.26on TipRanks Aug 6 06:00 +5.0%next day +8.8% · 5 days +13.2%
Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% Craig-Hallum — Buy — Reiterated 08.07.26on TipRanks 12:36 −2.1%next day +3.5% · 5 days −0.1%
Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% Goldman Sachs $19.00 → $21.00+10.5% Hold −7.1% Reiterated 07.11.25on TipRanks 13:45 −4.8%next day +1.3% · 5 days −0.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Schrodinger

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Evan Seigerman★★★★★★★★★★BMO Capital · #856
Hits 59%289 of 494 Average return +9.3%
1 year Matt Hewitt★★★★★★★★★★Craig-Hallum · #3011
Hits 47%229 of 486 Average return +4.1%
2 years Matt Hewitt★★★★★★★★★★Craig-Hallum · #3011
Hits 47%229 of 486 Average return +4.1%

Most profitable

3 months Evan Seigerman★★★★★★★★★★BMO Capital · #856
Hits 59%289 of 494 Average return +9.3%
1 year Matt Hewitt★★★★★★★★★★Craig-Hallum · #3011
Hits 47%229 of 486 Average return +4.1%
2 years Matt Hewitt★★★★★★★★★★Craig-Hallum · #3011
Hits 47%229 of 486 Average return +4.1%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.00 at a price of $31.05 (−35.6%); now: $25.80 at $22.60 (+14.2%).

$20.00$25.00$30.00Sep 15Oct 1Oct 15Top analysts$24.25Average target$25.80Price$22.60

PriceAverage targetTop analysts’ target

Recommendation trend

051015973Oct 25353Nov382Dec284Jan 26482Feb373Mar441Apr362May361Jun271Jul93Aug74Sep84Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy332000
Buy667978
Hold211344
Sell000000

Earnings and sales forecast

Next report: 11.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.67 (from $-0.81 to $-0.53). Last quarter: $0.08.

Sales

Next quarter’s sales estimate — $48M (from $35M to $53M). Last quarter: $59M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Data from the stock’s TipRanks forecast page, read 34 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗